Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies. Preliminary data from the study showed that IPI-145 was well tolerated to date and clinically active in patients with both B-cell and T-cell malignancies, including chronic lymphocytic leukemia, indolent non-Hodgkin’s lymphoma, mantle cell lymphoma, Hodgkin’s lymphoma and T-cell lymphoma. These findings were presented today at the 54 th Annual Meeting of the American Society for Hematology (ASH) in Atlanta, Georgia.
“Data from this Phase 1 trial of IPI-145 show good tolerability and rapid clinical responses across a broad spectrum of difficult-to-treat hematologic malignancies,” commented Ian Flinn, M.D., Ph.D., director, hematologic malignancies research program, Sarah Cannon Research Institute, and an investigator for the trial. “These data are especially encouraging considering that the dose escalation phase of this study is still ongoing, so we look forward to the further clinical evaluation of IPI-145.”
“These results reinforce our enthusiasm for IPI-145. We believe that the potency and activity of IPI-145 against both PI3K-delta and PI3K-gamma contribute to its potential to become the best-in-class PI3K inhibitor for the treatment of hematologic malignancies,” stated Julian Adams, Ph.D., president of R&D at Infinity. “In particular, we believe the data presented today at ASH are the first to show activity against T-cell lymphoma by a PI3K inhibitor. We look forward to expanding the trial in additional cohorts of patients at or below the maximum tolerated dose.”
IPI-145 Data Presented at ASHThe poster, “Clinical safety and activity in a Phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase (PI3K)-delta,gamma in patients with advanced hematologic malignancies” (Abstract #3663), includes 55 patients evaluable for tolerability and 41 patients evaluable for clinical activity as of the November 20, 2012, data cutoff.